제약산업 구조분석과 발전방향(Structure analysis and improving strategies on pharmaceutical industry)

노트 : In 2010, the pharmaceutical industry accounted for 1.43% of Korea’s GDP, with a considerable influence on the national economy. So, the government has enacted laws and reorganized institutions to foster the pharmaceutical industry as a global pharmaceutical conglomerate. Nevertheless, the Korean pharmaceutical companies still remain small. These companies are overly profit-oriented, focusing on sales rather than R&D. Their business structure has been often criticized as inimical to the competitiveness of the Korean pharmaceutical industry. In addition, as the national health spending has continuously increased due to population ageing, reducing pharmaceutical spending accounting for 30% of health insurance reimbursement will have a great effect on the future of the pharmaceutical industry. This study analyzes the changing environment of the pharmaceutical industry and the structural characteristics of the Korean pharmaceutical industry from various perspectives, and draws measures to improve its structures and to gain it competitive edge based on the analysis